Company code: Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) company abbreviation: Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021 Annual Report
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 Unprofitable and unprofitable when the company is listed □ yes √ no III. prompt of major risks
Please refer to the details of the risks that the company may face in the production process described in Section III and Section IV of this report. 4、 All directors of the company attended the board meeting. 5、 Dahua Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6、 Liu Yujing, the person in charge of the company, Zhao Lingyang, the person in charge of accounting, and Yan Weijun, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The profit distribution plan for 2021 approved by the board of directors of the company is: the company plans to distribute profits based on the total share capital registered on the date of equity distribution, and plans to distribute cash dividends of RMB 2.65 (including tax) to all shareholders for every 10 shares. As of December 31, 2021, the total share capital of the company is 80000000 shares. Based on this calculation, the total cash dividend to be distributed is 2120000000 yuan (including tax). The company's cash dividend accounts for 20.06% of the net profit attributable to the shareholders of the parent company in this year. After this profit distribution, the remaining undistributed profits are accumulated and distributed in future years. In 2021, the company did not give bonus shares and did not convert capital reserve into share capital. If the total share capital of the company changes before the date of equity distribution and equity registration, the company plans to keep the total distribution unchanged and adjust the distribution proportion per share accordingly.
The company's profit distribution plan for 2021 has been deliberated and approved at the 16th meeting of the first board of directors, and needs to be submitted to the company's 2021 annual general meeting for deliberation and approval. 8、 Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable IX. risk statement of forward-looking statements √ applicable □ not applicable
This report involves forward-looking statements such as future plans and does not constitute the company's substantive commitment to investors. Please pay attention to investment risks. 10、 Is there any non operational occupation of funds by the controlling shareholders and their related parties? No
11、 Whether there is any external guarantee in violation of the specified decision-making procedures? No 12. Whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? No 13. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators 8 section III Management Discussion and Analysis Section IV corporate governance Section V environment, social responsibility and other corporate governance 94 section VI important matters Section VII changes in shares and shareholders 139 Section VIII preferred shares Section IX corporate bonds Section x financial report one hundred and fifty-two
1、 Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor).
Catalogue of documents for future reference II. The original audit report with the seal of the accounting firm and the signature and seal of the certified public accountant.
3、 The originals of all company documents and announcements publicly disclosed on the designated information disclosure media of the company during the reporting period.
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company, the company and the issuing company Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) , are wholly changed and established by Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) pharmaceutical research group, Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) and Co., Ltd., which can also refer to Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Co., Ltd. according to the context
stock company
Langyan life refers to Beijing Langyan life science and Technology Co., Ltd. and Beijing Langyan Life Technology Holding Co., Ltd
Sunshine Demi refers to Beijing Sunshine Demi Pharmaceutical Technology Co., Ltd
Novotel refers to Beijing Novotel Pharmaceutical Technology Co., Ltd
Novotel Shengtai refers to Chengdu Novotel Shengtai Biotechnology Co., Ltd
Hongsheng pharmaceutical refers to Beijing Hongsheng Pharmaceutical Technology Co., Ltd
Novo Billiton refers to Jiangsu novo Billiton new drug research and Development Co., Ltd
Novotel Hengguang refers to Beijing Novotel Hengguang Pharmaceutical Technology Co., Ltd
Novotel Shenghong refers to Chengdu Novotel Shenghong biopharmaceutical Co., Ltd
Novotel Shengxin refers to Chengdu Novotel Shengxin Testing Technology Co., Ltd
Paisixin refers to Shanghai paisixin Biomedical Technology Co., Ltd
Xianning pharmaceutical refers to Nanjing Xianning Pharmaceutical Technology Co., Ltd
Baiao pharmaceutical refers to Beijing Baiao Pharmaceutical Co., Ltd
Yongan pharmaceutical refers to Jiangsu Yongan Pharmaceutical Co., Ltd
Shengpu pharmaceutical refers to Chengdu Shengpu Pharmaceutical Technology Center (limited partnership)
Xinde phase I refers to Guangzhou Guangfa Xinde phase I health industry investment enterprise (limited partnership)
Xinde Aodong refers to Zhuhai Guangfa Xinde Aodong pharmaceutical industry equity investment center (limited partnership)
Minsheng investment refers to Minsheng Securities Investment Co., Ltd
Jilin Aodong Pharmaceutical Group Co.Ltd(000623) refers to Jilin Aodong Pharmaceutical Group Co.Ltd(000623)
Xinyu Zhongyou refers to Xinyu high tech Zone Zhongyou Investment Management Center (limited partnership)
Zhuhai qianheng refers to Zhuhai qianheng Investment Management Co., Ltd
Guangfa Qianhe refers to Guangfa Qianhe Investment Co., Ltd
Shengshan Yuying refers to Shanghai Shengshan Yuying venture capital center (limited partnership)
Shengshan Xingqian refers to Shanghai Shengshan Xingqian venture capital center (limited partnership)
Wuhan torch refers to Wuhan torch Venture Capital Co., Ltd
Wuxin fund refers to Wuhan credit fund management Co., Ltd
Wuhan development investment refers to Wuhan Development Investment Co., Ltd
Ruiying investment refers to Ningbo Haida Ruiying venture capital partnership (limited partnership)
Ruiying management refers to Ningbo Haida Ruiying Equity Investment Management Co., Ltd
Yidaoxin refers to Suzhou yidaoxin Investment Co., Ltd
Zhongyu Yingjia refers to Suzhou Zhongyu Yingjia health investment partnership (limited partnership)
Hangzhou Fangyu refers to Hangzhou Fangyu investment partnership (limited partnership)
Tianjin Mingfu refers to Tianjin Mingfu Technology Center (limited partnership)
Haidaminde refers to Hangzhou haidaminde venture capital partnership (limited partnership)
Kaitai minde refers to Hangzhou Kaitai minde investment partnership (limited partnership)
Hongteng pharmaceutical refers to Hangzhou Hongteng pharmaceutical venture capital partnership (limited partnership)
Kaitai Ruide refers to Hangzhou Kaitai Ruide investment partnership (limited partnership)
Jiaxing Gade refers to Jiaxing Gade equity investment partnership (limited partnership)
TEDA Shenglin refers to Tianjin TEDA Shenglin venture capital partnership (limited partnership)
Guangzhou Zhengda refers to Guangzhou Zhengda venture capital partnership (limited partnership)
Huipuzhifang refers to Hangzhou huipuzhifang equity investment partnership (limited partnership)
Foshan Jingxiang refers to Foshan Jingxiang Chuangli equity investment partnership (limited partnership)
Gf Securities Co.Ltd(000776) refers to Gf Securities Co.Ltd(000776)
Wuxi Apptec Co.Ltd(603259) refers to Wuxi Apptec Co.Ltd(603259)
Pharmaron Beijing Co.Ltd(300759) refers to Pharmaron Beijing Co.Ltd(300759) (Beijing) new drug Technology Co., Ltd
Hangzhou Tigermed Consulting Co.Ltd(300347) refers to Hangzhou Tigermed Consulting Co.Ltd(300347)
Warwick pharmaceutical refers to Nanjing Warwick Pharmaceutical Technology Group Co., Ltd
New leading refers to Beijing new leading pharmaceutical technology development Co., Ltd
Joinn Laboratories (China) Co.Ltd(603127) refers to Joinn Laboratories (China) Co.Ltd(603127)
Hefei future refers to Hefei future drug development Co., Ltd
The articles of association refers to the Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) articles of association
Sponsors and sponsors refer to the institutions of Minsheng Securities Co., Ltd., the accountant of the lead underwriter, and Dahua association refers to Dahua Certified Public Accountants (special general partnership) accounting firm
CSRC refers to the China Securities Regulatory Commission
Company law of the people's Republic of China
Securities Law refers to the securities law of the people's Republic of China
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan unless otherwise specified
The reporting period refers to January December 2021
The end of the reporting period refers to December 31, 2021
A share refers to domestic listed RMB ordinary shares
This issuance refers to the company's initial public offering of shares
Listing refers to the listing and trading of the issued shares on the stock exchange
Cro refers to the contract research organization, a company or other institution that provides specialized drug R & D services.
Preparation refers to the process and behavior of making a compound into the final drug form through the study of the physical and chemical properties of chemical combination, such as crystal form, and the final drug form that can be used directly by the human body.
New drugs include innovative drugs and improved new drugs. Innovative drugs refer to APIs and their preparations containing new compounds with clear structure and pharmacological effects and clinical value. Improved new drugs refer to the improvement of known active ingredients of innovative drugs, or the preparation of new dosage forms, new prescription processes, new routes of administration and new indications containing known active ingredients.
Generic drugs refer to APIs and their preparations with the same active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage as the original drugs.
The original drug refers to the first drug approved for listing at home and abroad, and has complete and sufficient safety and effectiveness data as the basis for listing.
The first generic drug refers to the first generic drug in China that imitates the original drug and is approved for marketing.
Reference preparation refers to the reference drug used for the evaluation of the consistency of quality and efficacy of generic drugs. It is usually the object of imitation, including the original drug or the internationally recognized same drug.
Consistency evaluation refers to the generic drugs approved for listing before the implementation of the new registration classification of chemical drugs. If they are not approved in accordance with the principle of consistency with the quality and efficacy of the originally developed drugs, the consistency evaluation shall be carried out in stages and batches in accordance with the principle of consistency with the quality and efficacy of the originally developed drugs.
Pharmaceutical research refers to the research on the synthesis of bulk drugs, formulation technology, impurities, stability and quality in the process of drug research and development.
Small test refers to the process of small batch trial production according to the laboratory experimental results.
Pilot test refers to the process of trial production on an enlarged scale on the basis of small-scale test before the product is officially put into production, but the scale is smaller than the scale of formal mass production.
Preclinical research mainly includes drug safety evaluation, pharmacokinetics and pharmacology
Clinical trial research refers to the systematic research of drugs in human body (patients or healthy volunteers) to confirm or reveal the effects and adverse reactions of test drugs and / or the absorption, distribution, metabolism and excretion laws of test drugs, with the purpose of determining the effectiveness and safety of test drugs. The clinical trial of innovative drugs is divided into four stages: phase I to IV; Imitation medicine Pro
